Related Experiment Video
Updated: Dec 29, 2025
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Allogeneic human umbilical cord-derived mesenchymal stem cells for severe bronchopulmonary dysplasia in children:
Xian Wu1,2,3, Yunqiu Xia1,2,3, Ou Zhou1,2,3
1Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, No 136, 2nd Zhongshan Rd, Yuzhong District, Chongqing, 400014, China.
Insights
This study investigates human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) for treating severe bronchopulmonary dysplasia (BPD) in infants. Results aim to establish hUC-MSC therapy as a new evidence-based treatment for BPD.
Area of Science:
- Neonatal medicine
- Regenerative medicine
- Pulmonology
Background:
- Bronchopulmonary dysplasia (BPD) is a common, severe chronic lung disease in preterm infants with limited effective treatments.
- Mesenchymal stem cells (MSCs) from human umbilical cord (hUC) show promise for improving lung injury and alveolarization.
- Intravenously administered allogeneic hUC-MSCs are being investigated for safety and efficacy in severe BPD.
Purpose of the Study:
- To evaluate the safety and efficacy of hUC-MSCs in children with severe BPD.
- To determine optimal dosage for hUC-MSC therapy in BPD patients.
- To provide evidence for a novel therapeutic approach for BPD.
Main Methods:
- A randomized, single-center, open-label, dose-escalation Phase II trial (MSC-BPD) involving 72 patients.
- Patients randomly assigned to receive low-dose (2.5 million cells/kg) or high-dose (5 million cells/kg) hUC-MSCs, or supportive care alone.
- Primary outcome: cumulative oxygen therapy duration; secondary outcomes: chest radiography changes over 24 months.
Main Results:
- The study is designed to evaluate the efficacy of hUC-MSC treatment.
- Statistical analyses will assess the impact of hUC-MSC doses on BPD outcomes.
- Interim or final results are pending publication.
Conclusions:
- This is the first randomized controlled trial assessing intravenous hUC-MSCs for severe BPD in children.
- The study aims to provide new, evidence-based therapeutic options for severe BPD.
- Findings could significantly impact the management of chronic lung disease in neonates.
Background:
Bronchopulmonary dysplasia (BPD) is a complex lung pathological lesion secondary to multiple factors and one of the most common chronic lung diseases. It has a poor prognosis, especially in preterm infants. However, effective therapies for this disease are lacking. Stem-cell therapy is a promising way to improve lung injury and abnormal alveolarization, and the human umbilical cord (hUC) is a good source of mesenchymal stem cells (MSCs), which have demonstrated efficacy in other diseases. We hypothesized that intravenously administered allogeneic hUC-MSCs are safe and effective for severe BPD.
Methods:
The MSC-BPD trial is a randomized, single-center, open-label, dose-escalation, phase-II trial designed to investigate the safety and efficacy of hUC-MSCs in children with severe BPD. In this study, 72 patients will be enrolled and randomly divided into two intervention groups and one control group. Patients in the intervention groups will receive a low dose of hUC-MSCs (n = 24; 2.5 million cells/kg) or a high dose of hUC-MSCs (n = 24; 5 million cells/kg) in combination with traditional supportive treatments for BPD. The patients in the control group (n = 24) will be treated with traditional supportive treatments alone without hUC-MSCs. The primary outcome measures will be cumulative duration of oxygen therapy. Follow-up assessments will be performed at 1, 3, 6, 12, and 24 months post intervention, and the key outcome during follow-up will be changes on chest radiography. Statistical analyses will evaluate the efficacy of the hUC-MSC treatment.
Discussion:
This will be the first randomized controlled trial to evaluate the safety and efficacy of intravenously administered hUC-MSCs in children with severe BPD. Its results should provide a new evidence-based therapy for severe BPD.
Trial Registration:
ClinicalTrials.gov, ID: NCT03601416. Registered on 26 July 2018.
More Related Videos
04:09Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
Published on: March 3, 2023
07:26Isolation and Characterization of Human Umbilical Cord-derived Mesenchymal Stem Cells from Preterm and Term Infants
Published on: January 26, 2019